Free Trial

Jeet Mukherjee Analyst Performance

Analyst at BTIG Research

Jeet Mukherjee is a stock analyst at BTIG Research, covering 1 publicly traded companies across a range of sectors. Over the past year, Jeet Mukherjee has issued 1 stock ratings, including and buy recommendations. While full access to Jeet Mukherjee's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Jeet Mukherjee's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
1 Last 0 Years
Buy Recommendations
100.00% 1 Buy Ratings
Companies Covered
1 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%1 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
1 company

Jeet Mukherjee, an analyst at BTIG Research, currently covers 1 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
1 company
100.0%

Jeet Mukherjee of BTIG Research specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
1 company
100.0%

Jeet Mukherjee's Ratings History at BTIG Research

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
6/26/2025Reiterated Rating$46.47$59.00Buy